© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Raloxifene Hydrochloride stepped onto the pharmaceutical stage after researchers in the late 1980s spotted a clear need for more options in osteoporosis management and breast cancer prevention. Drawing on years of estrogen receptor exploration, scientists tried to find a compound that could protect bone without triggering excessive cell growth in breast or uterine tissue. After plenty of trials, setbacks, and head-scratching over unwanted side effects, Raloxifene stood out by offering just enough estrogen-like action in bones to prevent fractures, yet blocking those same hormone signals in reproductive tissues. The FDA gave its approval in 1997, giving clinicians a reliable alternative to traditional hormone therapy, which often came with complications nobody wanted. Patients who needed long-term support and fewer cancer risks found some hope in Raloxifene's arrival, marking a visible shift from “treat at all costs” drugs toward options with a far clearer risk-benefit picture.
Raloxifene Hydrochloride belongs to a group called Selective Estrogen Receptor Modulators (SERMs). It’s available mostly in tablet form, usually coated for better swallowing and protection from moisture. Most prescriptions stick to a 60 mg daily dose, tailored for bone loss prevention in postmenopausal women or to lower the likelihood of certain breast cancers. Manufacturers tend to pack them in blister cards to protect against air and sunlight, since the active compound can break down with too much exposure. Demand has stayed consistent over decades, thanks to aging populations and growing awareness about osteoporosis and preventive medicine.
In the lab, Raloxifene Hydrochloride pops out as a white to pale yellowish powder, with fine crystals that don’t dissolve much in water but handle organic solvents pretty well. Its chemical formula, C28H27NO4S·HCl, gives it a molecular weight around 510 g/mol when including its hydrochloride partner. Stability matters during shipping and in pharmacy storage, so controlled humidity and tight packaging keep it from turning sticky or clumping. Melting point clocks in over 230°C, showing off its sturdy backbone typical of many pharmaceutical-grade molecules that require safe handling. Taste and odor are usually not an issue in its final product forms, since coatings mask the bitterness and facilitate easier use for patients.
Every tablet batch is subject to rigorous identity, potency, and purity checks. Pharmaceutical quality standards—like those in the U.S. Pharmacopeia—force producers to measure precise amounts of active drug, control impurities, and guarantee no contamination. Labels must show the established name (Raloxifene Hydrochloride), strength, batch number, expiration date, storage conditions, manufacturer details, and clear dosing instructions. Some countries require extra labeling about pregnancy risks and potential side effects, especially since Raloxifene’s estrogen-blocking effects can harm fetal development. Packaging also has compliance with tamper-evidence rules and child-resistant closures where regulations demand it.
Raloxifene Hydrochloride comes from a multi-step synthesis, mostly starting with benzothiophene and piperidine ring structures. Organic chemists rely on condensation reactions, halogenation, and reduction steps to build up the skeletal framework. A critical stage involves forming the hydrochloride salt, boosting stability and bioavailability. This involves dissolving the base compound in solvents then adding hydrochloric acid to form the salt, followed by controlled crystallization. Purification usually takes several chromatographic runs—sometimes column or flash chromatography—before drying under reduced pressure packs the finished product. Every stage gets checked by spectroscopic tests—often HPLC, NMR, and IR—to rule out impurities.
Raloxifene’s backbone is built on a benzothiophene core, easily recognized in organic chemistry for its potential to form hydrogen bonds and interact with receptor proteins. Chemists have experimented with various substitutions at the piperidine and phenolic positions to tweak selectivity and strength for the estrogen receptor. Some groups swap in halogen or methoxy groups, hoping to push activity even further in breast or bone tissue targets. Research labs have also probed prodrug forms, attaching side chains meant to improve water solubility or make the drug stick around longer in the bloodstream before being snipped off enzymatically to release Raloxifene itself. While big changes to the parent compound often reduce its effectiveness or safety, minor modifications sometimes give clues to next-generation SERM development.
Raloxifene Hydrochloride moves under many flags around the globe. “Evista” stands as the most recognized brand, launched by Eli Lilly and used in hundreds of thousands of prescriptions. Other countries list it as “Optruma,” with the same core ingredient. Chemically using the International Nonproprietary Name (INN), it’s always “Raloxifene.” Some scientific literature uses descriptors like “LY139478,” a nod to the original research code. Whatever the label, pharmacies ensure they’re tracking with the approved monograph standards for consistency in strength and purity.
Safe handling guides every stage from synthesis to patient use. On the manufacturing side, protective gear is non-negotiable since fine powders can irritate the skin and mucous membranes. Pharmaceutical sites enforce containment and ventilation to keep airborne particles from drifting, protecting both workers and product integrity. Healthcare settings deal mostly with finished tablets; the lowest risks come from accidental ingestion by children or pregnant women, so packaging and clear warnings matter. Raloxifene Hydrochloride interacts with estrogen pathways, so patients with histories of clotting disorders or stroke typically get careful screening before starting a prescription. Pharmacovigilance programs gather real-world reports of serious side effects—especially blood clots and allergic reactions—to keep guidance current and grounded in everyday practice, not just clinical trials.
Doctors turn to Raloxifene Hydrochloride mostly for postmenopausal women facing bone loss, reducing the rate of fractures and hospitalizations. It’s also found a role in breast cancer prevention for high-risk women who can’t or won’t take tamoxifen. Some off-label exploration has touched on male osteoporosis and hormone-related disorders, although thorough evaluations keep use focused on clear evidence and regulatory approval. The drug also features in clinical guidelines across the world, slotting in behind bisphosphonates or other SERMs depending on availability, cost, and patient risk profiles. Its unique receptor-blocking and -activating abilities mean it can offer similar benefits to estrogen without the cascade of serious risks that pure hormone therapy brings.
Modern research often dives into fine-tuning the profile of SERMs to target not just bone and breast, but potentially metabolic syndrome, cardiovascular risk, and cognitive decline linked with aging. Studies continue to ask whether adjusting Raloxifene’s dose or pairing it with vitamins or bisphosphonates could stretch its benefits even further. Genetic research sometimes uncovers which patients respond best based on specific receptor mutations in bone or tumor cells. On the molecular side, medicinal chemists look for ways to patch up Raloxifene’s relatively low water solubility and its variable absorption in different patient groups. Pharmacoepidemiology tracks outcomes over years, weighing rates of fracture, cancer, cardiovascular events, and real-life adherence—a reminder that pills only work if people stick with taking them.
Every developing drug faces a gauntlet of toxicity testing, and Raloxifene Hydrochloride proved no different. Early animal studies set dose thresholds for liver, kidney, and reproductive organ changes, along with a close look for cancer or blood abnormalities. The results pointed to thrombosis—that’s blood clot risk—especially in women with previous clotting issues or who mix long periods of sitting with other risk factors. The medical community keeps a close watch through registries and post-market studies, occasionally revising guidelines as experience grows. Recent studies hint that while most patients tolerate daily doses well, adding Raloxifene to regimens with other hormone drugs or blood thinners demands real vigilance and active monitoring. This brings a focus on patient education and regular follow-up, especially in older adults with multiple health conditions.
Raloxifene Hydrochloride probably won’t fade from view as the population ages and the number of women at risk of bone loss keeps climbing. With drug discovery embracing artificial intelligence and big data, future analogs may trim away even more side effects, or adapt the SERM model for men and younger patients. Meanwhile, combination therapies—mixing small doses with calcium, vitamin D, or anti-inflammatory agents—generate attention for those hoping to amplify benefits without piling on more pills. The next wave of research might spot long-term benefits for cardiovascular or cognitive health, widening its reach. Pricing, access, and public health policies will also dictate how many people benefit, particularly in developing countries where osteoporosis often goes undiagnosed. This drug started as a specialist tool for a narrow band of patients; time and science may grant Raloxifene Hydrochloride a broader future, if today’s investment in research and real-world safety tracking holds steady.
Osteoporosis quietly chips away at bone strength, especially in postmenopausal women. Countless women only learn about their bone thinning after a break or fracture. Raloxifene hydrochloride steps in here as a protector. My own mother first heard her bone density was dropping in her fifties. Her doctor explained that this medication, originally developed by Eli Lilly, helps slow down the loss of bone tissue, which means fewer broken hips or wrists in the years to come.
Raloxifene looks and acts a lot like estrogen inside the body, but it isn’t the real hormone. Estrogen drops sharply after menopause, sending bone-building cells into a decline. Scientists call drugs like raloxifene "selective estrogen receptor modulators" (SERMs). This mouthful means they mimic the good parts of estrogen in bones and block its dangerous effects elsewhere.
The FDA approved raloxifene hydrochloride to both prevent and treat osteoporosis in postmenopausal women. Studies have shown it reduces spinal fractures by about 30 to 50 percent, an impressive leap from doing nothing. No drug solves everything, but this one gives bones a fighting chance. I’ve seen older relatives stronger and more independent thanks to medications like this.
Raloxifene doesn’t just help bones. Doctors also prescribe it for some women at high risk of breast cancer. According to research, it lowers the odds of invasive breast cancers by turning off the switches that feed tumor growth. For women with a family history or other risk factors, that’s huge. Knowing my aunt carries some genetic risk, her relief after her oncologist discussed the drug’s track record stuck with me.
As with most medicines, the good comes with some caution. Blood clots, hot flashes, and leg cramps can show up, so doctors look at the full picture before prescribing. Regular check-ups help spot trouble early. It’s worth talking about the potential for deep vein thrombosis with anyone considering the medication.
The world’s population is growing older, and more women than ever face osteoporosis and breast cancer risks. About one in three women over 50 suffers a fracture related to bone thinning. Costs for surgery, recovery, and lost independence add up fast. Drugs like raloxifene don’t replace healthy eating and exercise, but they offer an added layer of protection. The National Osteoporosis Foundation and American Cancer Society both reference raloxifene as a valid tool, not just a last resort.
Prescription costs and insurance coverage still block access for some patients. Generics help with affordability. Expanding screening and education would reach more women who could actually benefit but haven’t heard the details. I grew up in a small town where osteoporosis just meant "getting old," so getting the facts into local clinics and community talks makes a real difference.
Ongoing research watches for who gains the most and who faces side effects. Genetic studies may soon fine-tune which women should consider raloxifene or look for other options. Better access to bone scans in local healthcare centers creates earlier diagnoses, opening the door for early treatment and fewer broken bones.
Raloxifene hydrochloride stands out because it helps on two major health fronts at once. By making these tools available to more people and starting conversations early, more women get the chance to age with fewer setbacks and enjoy more freedom in their later years.
Doctors prescribe Raloxifene Hydrochloride mostly to women after menopause. It works to strengthen bones and cut down the chance of fractures. As with many medications, people ask about side effects almost right away in the clinic. Most want to know if they can expect anything unusual, and what to do if it happens.
Hot flashes stand out as an unwanted guest for many women starting raloxifene. The feeling can rush over you—sudden warmth, a flushed face, a sweaty back. This side effect reminds me of the stories I’ve heard from patients who try hormone therapies or go through menopause itself. For some, it shakes sleep. For others, it becomes just another hallway echo in a day filled with distractions. Staying cool, drinking water, and dressing in layers offers relief. Talking about it with your healthcare team helps. Sometimes, people decide the trade-off for stronger bones is worth it, even with these heat waves.
Leg cramps visit the lives of a fair number of raloxifene users. I remember a neighbor, Joyce, who called them “nighttime nuisances.” She found stretching before bed and staying active in the daytime helped tone them down. Some women mention swelling in their legs, too—an issue that’s tough for those already keeping an eye on heart health or blood vessels. The risk of deep vein blood clots means regular movement becomes even more important. If swelling or pain grows, a quick trip to the doctor often sorts out the cause and next steps.
Blood clots spark real concern, and for good reason. Raloxifene increases the chance of clots forming in legs or lungs. Studies show this risk sits close to what women see with hormone therapies. Doctors double-check if someone has a history of clots or will stay immobile after surgery. Moving around on flights, keeping hydrated, and recognizing symptoms—like sudden leg pain or sharp chest pain—matter here. Information gives power, not panic.
People sometimes talk about mild side effects. Sweating, joint aches, or a touch of swelling pop up in conversations and online forums. For most, these pass or stay manageable. Constipation appears more often in the first weeks. Drinking more fluids, adding fiber, and gentle exercise often keep digestion on track. Itching or a rash may show up rarely, but if it happens, a doctor’s advice makes a difference.
Sometimes patients ask about long-term safety. Clinical research and practice give a good idea of what to expect. Raloxifene can lower breast cancer risk along with helping bones. For many, that trade-off tips the scale toward taking the medicine. Regular checkups, honest talks about new symptoms, and knowing personal risk help individuals get the most from raloxifene while cutting down trouble spots. In my own experience, the stories people share in the office teach more than textbooks alone.
Each person’s response to raloxifene carries its own stamp. Sharing symptoms early, being honest about worries, and keeping follow-up visits makes for stronger health. With clear information and a doctor who listens, many move through rough patches and get back to everyday life with steadier bones beneath them.
My aunt used to talk about how her bones felt weaker as she aged. Her doctor prescribed something called raloxifene hydrochloride, explaining it could help her fight off osteoporosis. I sat with her as she tried to make sense of the directions, realizing these instructions affect so much more than just a daily routine—they impact how well this medicine works and how safe she feels using it.
The Food and Drug Administration has given raloxifene its stamp after trials showed it can both slow bone loss in postmenopausal women and lower the risk of invasive breast cancer. That’s a strong case for following guidelines as closely as possible. Every year in the U.S., about 10 million people face osteoporosis, with most being women over 50. For these women, missing doses or not taking it correctly means missing out on its protection. Sticking to a set routine helps you get the best shot at stronger bones over time.
Doctors usually recommend taking one tablet of raloxifene a day. The label says you can swallow it with or without food, so it fits pretty easily into breakfast or an evening snack. My aunt liked to tie her dose to her oatmeal, so she never forgot. Water always helps to wash it down. Since high doses won’t ramp up the benefit but can raise the odds of side effects, more is not better. Skipping doses happens to everyone once in a while. Missing one day? Just take the next pill as normal—the body forgives a bump or two, but don’t double up.
I remember hearing her talk about leg cramps and hot flashes. These side effects can pop up, and even though most people get through them just fine, they shouldn’t be brushed aside. Raloxifene does raise the risk of blood clots, which can turn into a serious emergency. That risk climbs if you sit still for long spans—think car trips or recovery after surgery. My aunt’s doctor reminded her to keep moving and talk about any sudden swelling or trouble breathing. Clear communication like this builds trust, and saves lives.
It’s not just about the medication. Raloxifene works alongside the basics: enough calcium, enough vitamin D, daily movement. Many people fall short on these without thinking about it. My aunt’s doctor checked her vitamin D level before starting, and pointed her toward small dietary changes. That mix—medicine and lifestyle—brings better results than either alone.
Taking raloxifene holds real promise, but it asks for a plan. Break routine, and the benefits fade. Pair it with healthy habits, and protection grows. Keeping a medicine log, asking questions at every medical visit, watching for changes in how you feel—these small steps hold more weight than any scientific paper can express. After seeing my aunt carry these lessons forward, I know that the details of “how to take it” often end up being the key to gaining strength, not just for your bones, but for your confidence day-to-day.
Raloxifene hydrochloride treats osteoporosis in postmenopausal women and reduces the risk of invasive breast cancer. It acts a bit like estrogen in some parts of the body but blocks estrogen in others. The whole goal is to strengthen bones and protect certain tissues, but it comes with its own set of rules and watch-outs.
Mixing raloxifene with warfarin or other blood thinners can cause problems. Warfarin relies on a steady balance to keep blood from getting too thin or too thick. Raloxifene alters clotting times for some people, so the doctor may check blood work more often or adjust the dose. Anyone on blood thinners already keeps a close eye on bruising or unusual bleeding. Adding raloxifene just calls for even more vigilance.
Cholestyramine, colestipol, and colesevelam help lower cholesterol but can mess with raloxifene absorption. These resins bind up the drug in the gut, leaving less to enter the bloodstream, which reduces its bone-strengthening effect. If doctors prescribe both, separating the doses by at least six hours cuts down on waste. It’s not always convenient, but it’s simple and works well.
Lots of people grab calcium and vitamin D without thinking twice, especially if osteoporosis comes up. Those two don’t clash directly with raloxifene, so they can usually be taken together to help out brittle bones. Still, some herbal supplements like St. John’s wort affect how drugs break down in the body. If you toss a new supplement into the mix, ask the doctor or pharmacist just in case.
Food itself doesn’t block raloxifene. Taking it with or without food doesn’t impact absorption. Grapefruit and its juice, known for stirring up trouble with some medications by blocking liver enzymes, don’t interfere with this drug. That said, anyone with risk of blood clots needs to focus on hydration and avoid sitting still for too long, not so much individual foods.
Doctors don’t just caution patients about food and medicine as a formality. Years working with older adults taught me that most health scares start with crossed wires. Two pills in the same cup, or a new prescription that the pharmacist didn’t know about, can mean the difference between safe treatment and a hospital trip. Medications like raloxifene aren’t a “set it and forget it” deal, especially when other chronic conditions pop up at the same time.
Write down every medication, supplement, or herbal remedy you take and hand that list to your pharmacist and primary doctor. Keep prescription records up to date. Always check before mixing anything new with raloxifene, since doctors see interactions before they turn into real trouble. If something feels off—swelling in the legs, shortness of breath, sudden pain—make the call right away. The risks with raloxifene build slowly, and catching a problem early is always the best way forward.
Raloxifene hydrochloride changes how bones and some tissues handle estrogen, so it helps some women face osteoporosis with less risk for certain cancers. That said, not everyone with weakened bones or fear of cancer benefits from it. People dealing with blood clots—past or present—should get the facts before starting this medicine. Sitting in a hospital room and hearing a doctor talk about blood clot risks has a way of making pills seem less innocent.
Having seen family members deal with deep vein thrombosis or pulmonary embolism, it’s clear how miserable and risky clots can be. Raloxifene ramps up clotting risks, so anyone with a track record of clots, strokes, or those recovering from severe injuries usually hears a hard “no” from their physician. The FDA put black box warnings on this drug for a reason. Stories from hospital wards keep repeating: women arrive with leg pain, then doctors tie the dots back to medicines like raloxifene.
Pregnancy and raloxifene definitely don’t belong together. This drug blocks estrogen in certain tissues, and that has spelled disaster for developing babies in animal studies. Even if chances of pregnancy seem low, with women past menopause, certainty matters. The FDA keeps it out of reach for anyone pregnant or possibly pregnant because nobody wants to see another generation learn this lesson the hard way.
Healthy organs help process medication, and that stands doubly true for liver and kidneys. Folks facing liver disease, chronic kidney trouble, or weak filtration function really need expert advice before thinking about raloxifene. Liver problems change how this drug breaks down, and it can stick around too long—raising chances for side effects. This isn’t speculation: studies on medication levels in people with liver trouble show higher drug buildup, raising unwanted reactions.
Staying in bed after an operation or injury slows blood flow—a top cause for clot problems. Raloxifene multiplies the odds even more; so doctors tend to pull the plug on this pill at least three days before scheduled surgery or long-term bed rest. Most hospitals add this to their checklist for anyone on the drug. It’s an easy step, but one that makes big difference in avoiding complications that could’ve been avoided.
Anyone with allergies to raloxifene or any of its ingredients needs to steer clear. Allergies don’t give warnings—they hit fast, and anaphylactic reactions demand emergency help. Beyond that, certain medicines don’t mix well with raloxifene, including estrogens or drugs that affect blood clotting. Pharmacists keep long lists of what shouldn’t be mixed, so it never hurts to ask before adding a new drug to your routine.
Raloxifene offers real benefits for some women, especially with osteoporosis and after menopause. But nobody can ignore these risks. If blood clots, liver or kidney disease, pregnancy, or major surgery are in the picture, skipping this medication makes sense. Pharmacists and doctors have the facts; leaning on their experience and checking your history can help travelers on this road avoid unnecessary problems. Sometimes the hardest thing is saying no when you want relief, but sometimes no is the smartest move.
| Names | |
| Preferred IUPAC name | 2-(4-hydroxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)benzoyl]benzothiophen-6-ol;hydrochloride |
| Other names |
Evista Keoxifene Ralista Optruma |
| Pronunciation | /rəˈlɒksɪfiːn haɪˌdrɒkləˈraɪd/ |
| Identifiers | |
| CAS Number | [82640-04-8] |
| 3D model (JSmol) | `3DModel:JSmol|Raloxifene_Hydrochloride|C28H28ClNO4S` |
| Beilstein Reference | 14230052 |
| ChEBI | CHEBI:8374 |
| ChEMBL | CHEMBL1200969 |
| ChemSpider | 143390 |
| DrugBank | DB00481 |
| ECHA InfoCard | echa-info-card-100000689893 |
| EC Number | 130462-22-3 |
| Gmelin Reference | 956507 |
| KEGG | D08746 |
| MeSH | D017047 |
| PubChem CID | 150274 |
| RTECS number | VI7918000 |
| UNII | 6TAS1O1VD6 |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C28H28ClNO4S·HCl |
| Molar mass | 510.04 g/mol |
| Appearance | White to pale yellow powder |
| Odor | Odorless |
| Density | 1.3 g/cm3 |
| Solubility in water | Soluble in water |
| log P | 5.5 |
| Acidity (pKa) | 8.95 |
| Basicity (pKb) | 7.64 |
| Magnetic susceptibility (χ) | -77.9×10^-6 cm³/mol |
| Refractive index (nD) | 1.786 |
| Dipole moment | 4.49 D |
| Pharmacology | |
| ATC code | G03XC01 |
| Hazards | |
| Main hazards | Suspected of causing cancer. |
| GHS labelling | GHS labelling of Raloxifene Hydrochloride: "Warning, H302, H315, H319, H335, P261, P305+P351+P338, P304+P340 |
| Pictograms | pictograms: ["health-hazard", "environment", "exclamation-mark"] |
| Signal word | Warning |
| Hazard statements | Hazard statements: H302, H315, H319, H335 |
| Precautionary statements | Keep out of reach of children. Obtain special instructions before use. If exposed or concerned: Get medical advice/attention. Dispose of contents/container in accordance with local/regional/national/international regulations. |
| Flash point | > 233.7 °C |
| Autoignition temperature | 700°C |
| Lethal dose or concentration | LD50 Oral Rat > 5000 mg/kg |
| LD50 (median dose) | LD50 (median dose): > 5000 mg/kg (rat, oral) |
| PEL (Permissible) | Not established |
| REL (Recommended) | 60 mg once daily |
| IDLH (Immediate danger) | IDLH (Immediate danger) data for Raloxifene Hydrochloride is not established. |
| Related compounds | |
| Related compounds |
Bazedoxifene Tamoxifen Toremifene Clomifene Ospemifene Fulvestrant |
